Activity Overview
Clinical Crossroads™ uses a unique case-based format featuring a series of patient-clinician videos that follow the journey of a patient with Lambert-Eaton myasthenic syndrome (LEMS), a rare neuromuscular junction disorder that is often misdiagnosed as myasthenia gravis. Through realistic clinical encounters and expert faculty discussion, learners will explore the differential diagnosis of LEMS, review key technical considerations for accurate diagnosis, and examine evidence-based approaches to management. The videos also highlight the potential consequences of delayed diagnosis and underscore the importance of timely recognition and appropriate treatment.
Target Audience
This educational initiative is directed toward neurologists, physician assistants, and other health care professionals involved in the diagnosis and management of neuromuscular disorders.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Review the clinical presentation of LEMS
- Formulate a differential diagnosis for patients with suspected LEMS
- Apply diagnostic criteria to identify patients with LEMS in a timely manner
- Integrate optimal therapies into management plans for patients with LEMS
Katherine Ruzhansky, MD, MS
Professor of Neurology
Director, Neuromuscular Division and EMG Lab
Medical University of South Carolina
Charleston, SC
Disclosures: Grant/Research Support: Immunovant, Janssen, UCB; Advisor, Consultant, Speaker, Honoraria Recipient: Alexion, Argenx, Immunovant, Janssen, UCB
Perry Shieh, MD, PhD, FAAN
Professor of Neurology and Pediatrics
David Geffen School of Medicine at UCLA
Neuromuscular Neurologist
UCLA Health
Los Angeles, CA
Advisor, Consultant, Fee-for-Service Recipient: Alexion, Amgen, Argenx, Biogen, Catalyst, CSL Behring, Grifols, Johnson & Johnson, Novartis, Roche, Sarepta, UCB. Speaker’s Bureau: Alexion, Amgen, Argenx, Biogen, Catalyst, CSL Behring, Grifols, Johnson & Johnson, Novartis, Roche, UCB. Grant/Research Funding: Abcuro, AMO Pharma, Arcellx, ARTHEx Biotech, Astellas, Avidity Biosciences, Biogen, Cartesian Therapeutics, Dyne, Edgewise, Epicrispr Bio, NMD Pharma, Novartis, Pfizer, PTC Therapeutics, Sarepta, Solid
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
